AttendMe Owl Logo
AttendMe
Sign In
All Pathways
Critical CareManagement

Neuromuscular Blockade in ARDS

Neuromuscular Blockade in ARDS: Moderate-Severe ARDS on Mechanical Ventilation → Optimize Ventilation & Sedation First → Ventilator Dyssynchrony Despite...

Interactive Decision Tree

Mini Map

Algorithm Steps

  1. ▶
    Start

    Moderate-Severe ARDS on Mechanical Ventilation

    P/F ≤150 despite lung protective ventilation

    1. ●
      Action

      Optimize Ventilation & Sedation First

      NMBA is NOT first-line

      • Lung protective ventilation (Vt 4-8 mL/kg PBW)
      • Adequate sedation (RASS -4 to -5 if NMBA planned)
      • Optimize PEEP per protocol
      • Address reversible causes
      1. ◆
        Decision

        Ventilator Dyssynchrony Despite Deep Sedation?

        Patient-ventilator asynchrony causing harm

        • High plateau pressures
        • Flow dyssynchrony
        • Double triggering
        • Breath stacking
        1. ●
          Action

          Continue Without NMBA

          NMBA not routinely recommended

          • Continue lung protective ventilation
          • Optimize sedation
          • Consider prone positioning
          • Daily reassessment
        2. ◆
          Decision

          Consider NMBA in Select Patients

          ATS 2024: Conditional recommendation

          • Severe ARDS (P/F <100)
          • Dyssynchrony despite optimal sedation
          • High driving pressures
          • Early ARDS (<48h)
          1. ⚠
            Warning

            ⚠️ CRITICAL: Ensure Deep Sedation FIRST

            Awareness during paralysis is catastrophic

            • Target RASS -4 to -5
            • BIS monitoring if available (target 40-60)
            • Adequate analgesia
            • NEVER paralyze without deep sedation
            1. ◆
              Decision

              NMBA Strategy

              Intermittent bolus vs continuous infusion

              1. ●
                Action

                Intermittent Bolus (Preferred if Light Sedation)

                May be safer if light sedation maintained

                • Cisatracurium 0.1-0.2 mg/kg PRN
                • Or rocuronium 0.6-1 mg/kg PRN
                • For brief periods of dyssynchrony
                • Lower risk of prolonged weakness
                1. ●
                  Action

                  Monitoring on NMBA

                  Essential safety checks

                  • Train-of-four q4h (target 1-2/4)
                  • BIS if available (40-60)
                  • Eye protection (artificial tears)
                  • DVT prophylaxis
                  • Daily sedation/paralysis vacation trial
                  1. ◆
                    Decision

                    Daily Assessment: Still Needed?

                    Goal: shortest duration possible

                    1. ●
                      Action

                      Discontinue NMBA

                      When dyssynchrony resolved or ARDS improving

                      • Stop infusion, allow to wear off
                      • Ensure TOF 4/4 before lightening sedation
                      • Monitor for residual weakness
                      • Begin early mobilization protocol
                      1. ✓
                        Outcome

                        NMBA Discontinued

                        Continue ARDS management without paralysis

                    2. ●
                      Action

                      Continue NMBA

                      Ongoing indication present

                      • Document clear indication daily
                      • Minimize dose to achieve synchrony
                      • Plan for discontinuation
              2. ●
                Action

                Continuous Infusion

                For persistent severe dyssynchrony

                • Cisatracurium: 1-3 mcg/kg/min
                • Monitor TOF (train-of-four): target 1-2/4
                • Daily interruption to assess need
                • Limit duration <48h if possible

Guideline Source

An Update on Management of Adult Patients with Acute Respiratory Distress Syndrome: ATS Clinical Practice Guideline

DOI: 10.1164/rccm.202311-2011STView Guideline

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • Evidence is conflicting (ACURASYS vs ROSE trials)
  • Requires deep sedation - must optimize sedation first
  • Risk of ICU-acquired weakness with prolonged use
  • Train-of-four monitoring recommended
  • Does not address NMBA for intubation

Contraindicated Populations

pediatric

Applicable Regions

USEUGlobal

Global: Based on ATS 2024 guidelines

Version 1Next review: 2028-01-01

Related Critical Care Pathways

Acute Hypoxic Respiratory Failure Initial Management

Emergency

ARDS Mechanical Ventilation Management

Management

Corticosteroids in Septic Shock and ARDS

Management

Fluid Resuscitation in Septic Shock

Management

Next steps

Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.

Calculator

APACHE II Score

ICU mortality prediction using acute physiology and chronic health evaluation

Open page

Compare

AttendMe.ai vs DynaMed

See how this pathway workflow compares against DynaMed.

Open page

Commercial

Start free

Run the pathway in a live AttendMe account with citations and tracked usage.

Start free

Related Resources

All Clinical PathwaysClinical CalculatorsAI Chat with Auto-Detection

Frequently Asked Questions

What is the Neuromuscular Blockade in ARDS?

The Neuromuscular Blockade in ARDS is a management clinical algorithm for Critical Care. It provides a structured decision tree to guide clinical decision-making, based on An Update on Management of Adult Patients with Acute Respiratory Distress Syndrome: ATS Clinical Practice Guideline.

What guideline is the Neuromuscular Blockade in ARDS based on?

This algorithm is based on An Update on Management of Adult Patients with Acute Respiratory Distress Syndrome: ATS Clinical Practice Guideline (DOI: 10.1164/rccm.202311-2011ST).

What are the limitations of the Neuromuscular Blockade in ARDS?

Known limitations include: Evidence is conflicting (ACURASYS vs ROSE trials); Requires deep sedation - must optimize sedation first; Risk of ICU-acquired weakness with prolonged use; Train-of-four monitoring recommended; Does not address NMBA for intubation. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Neuromuscular Blockade in ARDS appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free